Question · from the living review of Obesity Pharmacotherapy →

Is it true that tirzepatide 15 mg weekly achieves mean body weight reduction of approximately 20–22% in adults with?

Established updated weekly · as of

Priors rates this Established — 93 out of 100, updated weekly. Yes — this looks well established. On the claim that tirzepatide 15 mg weekly achieves mean body weight reduction of approximately 20–22% in adults with, its four-agent AI review panel weighs the published, peer-reviewed evidence.

RefutedDoubtfulUncertainLikelyEstablished
where this sits on Priors’ scale of how settled the evidence is

How we got this answer. Priors runs each claim through a panel of four AI agents, each acting as a specialist expert reviewer. They read the published, peer-reviewed studies behind the question, judge how strong, consistent and reliable the evidence is, and turn that judgment into a single rating from 0 to 100 — refreshed every week as new studies appear, so it reflects where the evidence stands today, not a one-off verdict.

The traceable studies behind this rating — and the panel’s single strongest counter-argument to it — are in Priors’ full Obesity Pharmacotherapy review.

Related Metabolic & Endocrine questions

Is it true that semaglutide 2.4 mg weekly achieves a mean body weight reduction of approximately 15% from baseline i? → Is it true that more than 50% of people with obesity treated with semaglutide 2.4 mg weekly achieve at least 15% bod? → Is it true that semaglutide 2.4 mg weekly maintains clinically meaningful weight reduction (≥10%) through at least 1? → Is it true that more than one-third of people with obesity treated with tirzepatide 15 mg weekly achieve at least 25? →
Reflects the peer-reviewed evidence as of 17 July 2026 and updates as new studies land. AI can make mistakes. Not medical advice.